CRISPR Therapeutics (CRSP) Tops Q1 EPS by 107c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($0.67), $1.07 better than the analyst estimate of ($1.74). Revenue for the quarter came in at $100 million versus the consensus estimate of $25.85 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
• Elevance (ELV) PT Raised to $482 at Bernstein SocGen